Monoclonal antibody Ki‐67: its use in histopathology

Histopathology

Volumn 17, Issue 6, 1990, Pages 489-503

  BROWN, D C ^a   GATTER, K C ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

diagnostic value; Ki 67 antibody; proliferation index

Indexed keywords

MONOCLONAL ANTIBODY;

CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; BIOPSY; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CONNECTIVE TISSUE DISEASES; HUMAN; KI-67 ANTIGEN; LYMPHOPROLIFERATIVE DISORDERS; NUTRITION;

EID: 0025608960     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.1990.tb00788.x     Document Type: Article

References (138)

1. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables.
2. Review: assessment of cell proliferation in histological material.
3. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum.
4. Relationship of histologic features to behaviour of cystosarcoma phyllodes: analysis of ninety‐four cases.
5. Carcinoma of the cervix. Clinicopathologic correlation of 196 cases.
6. Mitotic counts in follicular lymphomas.
7. Mitosis counts: reproducibility and significance in grading of malignancy.
8. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumours of the uterus.
9. Histopathologists, malignancies and undefined high‐power fields.
10. Cell proliferation in health and disease.
11. The relationship between growth rate, labelling index and histological type of human solid tumours.
12. Cell‐cycle analysis using a monoclonal antibody to BrdUrd.
13. Flow cytometry: methodology and applications in pathology.
14. The role of immunocytochemistry in diagnostic pathology.
15. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.
16. Cell cycle analysis of a cell proliferation‐associated human nuclear antigen defined by the monoclonal antibody Ki‐67.
17. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki‐67.
18. The cell cycle associated change of the Ki‐67 reactive nuclear antigen expression.
19. Quantification and topographical description of Ki‐67 antibody labelling during the cell cycle of normal fibroblastic (MRC‐5) and mammary tumour cell lines (MCF‐7).
20. Ki‐67 detects a nuclear matrix‐associated proliferation‐related antigen. II. Localization in mitotic cells and association with chromosomes.
21. Cell cycle‐dependent reactivity with the monoclonal antibody Ki‐67 during myeloid cell differentiation.
22. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation‐associated antibody Ki‐67 and propidium iodide: analysis by flow cytometry.
23. Cell cycle dependent distribution of the proliferation‐associated Ki‐67 antigen in human embryonic lung cells.
24. 3H]‐thymidine labeling of S‐phase cells in solid mouse tumours.
25. 2 phase.
26. Comparison of monoclonal antibody Ki‐67 reactivity with grade and DNA flow cytometry of breast carcinomas.
27. Ki‐67 detects a nuclear matrix‐associated proliferation‐related antigen. I. Intracellular localization during interphase.
28. Cytoplasmic Ki‐67 expression: A reply to Dario Campana, Elaine Coustan‐Smith, and George Janossy.
29. Topoisomerase II: a specific marker for cell proliferation.
30. Analysis of proliferative grade using anti‐PCNA/cyclin monoclonal antibodies in fixed, embedded tissues.
31. Unique proliferation‐associated marker expressed on activated and transformed human cells defined by monoclonal antibody.
32. Immunocytochemical characterization of a monoclonal antibody that recognizes mitosing cells.
33. Preparation and preliminary characterization of monoclonal antibodies against human DNA polymerase
34. Double immunoenzymatic detection of surface phenotype of proliferating lymphocytes in situ with monoclonal antibodies against DNA polymerase α and lymphocyte membrane antigens.
35. 0.
36. Evolutionary conservation in various mammalian species of the human proliferation‐associated epitope recognized by the Ki‐67 monoclonal antibody.
37. Assignment of the gene(s) involved in the expression of the proliferation‐related Ki‐67 antigen to human chromosome 10.
38. Thymidine labeling index and Ki‐67 growth fraction in lesions of the breast.
39. Comparative analysis of different approaches to investigate cell kinetics.
40. Double immunocytochemical labeling of cell and tissue samples with monoclonal anti‐bromodeoxyuridine.
41. Relationship between labelling indices of Ki‐67 and BrdUrd in human malignant tumors.
42. The labelling index: a prognostic factor in head and neck carcinoma.
43. Labeling index as a prognostic marker in non‐Hodgkin's lymphoma.
44. Cell kinetic measurements of human tumors.
45. S‐phase rate as a predictor of early recurrences in carcinoma of the uterine cervix.
46. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long‐term survival.
47. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67.
48. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki‐67.
49. Immunohistological determination of proliferative activity in seminomas.
50. Proliferation in non‐Hodgkin's lymphoma: a comparison of Ki‐67 staining on fine needle aspiration and cryostat sections.
51. Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki‐67.
52. Growth fraction in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67.
53. Proliferative rates of non‐Hodgkin's lymphomas as assessed by Ki‐67 antibody.
54. Membrane transferrin receptor (TfR) and nuclear proliferation‐associated Ki‐67 expression in hemopoietic malignancies.
55. 3H]‐thymidine labelling index and monoclonal antibody Ki‐67 in non‐Hodgkin's lymphomas.
56. Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumours: a critical comparison of the monoclonal antibodies OKT9 and Ki‐67.
57. Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison with large cell lymphoma.
58. Cell proliferation in non‐Hodgkin's lymphomas. Digital image analysis of Ki‐67 antibody staining.
59. Ki‐67 expression in childhood acute lymphoblastic leukaemia and relation with L2 morphology.
60. The prognostic value of Ki67 immunostaining in non‐Hodgkin's lymphoma.
61. Prognostic relevance of tumour‐cell growth fraction in malignant non‐Hodgkin's lymphomas.
62. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki‐67.
63. A comparison of three methods for the determination of the growth fraction in non‐Hodgkin's lymphoma.
64. Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma.
65. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki‐67.
66. Diagnostic and prognostic value of monoclonal antibodies in immunophenotyping of angioimmunoblastic lymphadenopathy/lymphogranulomatosis X.
67. Diagnostic and prognostic value of immunohistological bone marrow examination: results in 212 patients with lymphoproliferative disorders.
68. Diagnostic and prognostic value of monoclonal antibodies in immunophenotyping of T cell lymphomas.
69. The utility of Ki67 immunostaining, nuclear organizer region counting, and morphology in the assessment of follicular lymphomas.
70. A comparison of nucleolar organizer region staining and Ki‐67 immunostaining in non‐Hodgkin's lymphoma.
71. The monoclonal antibody Ki‐67 as a marker for proliferating cells in sterotactic biopsies of brain tumours.
72. The use of the monoclonal antibody Ki‐67 in the identification of proliferating cells.
73. Relationship between Ki‐67 positive cells, growth rate and histological type of human intracranial tumors.
74. The use of the monoclonal antibody Ki‐67 in determination of the growth fraction in pediatric brain tumors.
75. The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI67. Application of the method to paraffin embedded specimens.
76. Growth fraction in human brain tumors defined by the monoclonal antibody Ki‐67.
77. Proliferative potential of meningiomas determined with the monoclonal antibody Ki‐67.
78. Growth rate of human pituitary adenomas.
79. Prognostic significance of Ki‐67 reactivity in soft tissue sarcomas.
80. Soft‐tissue sarcomas of adults: Study of pathological prognostic variables and definition of a histopathological grading system.
81. The grading of soft tissue sarcomas: Results of a clinicohistopathologic correlation in a series of 163 cases.
82. Multivariate analysis for histologic prognostic factors in 236 patients with soft tissue sarcomas.
83. Leiomyosarcoma of the kidney. Immunohistological and ultrastructural findings with special emphasis on the growth fraction.
84. Improved grading of bone tumors with the monoclonal antibody Ki‐67.
85. Proliferative index in breast carcinoma determined in situ by Ki‐67 immunostaining and its relationship to clinical and pathological variables.
86. Ki‐67 immunostaining in primary breast cancer: pathological clinical associations.
87. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast.
88. Prognostic significance of immunohistochemical parameters in breast carcinomas.
89. Growth fraction in breast cancers determined in situ with monoclonal antibody Ki‐67
90. The correlation of growth fraction with histologic grading and lymph node status in human mammary carcinoma.
91. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining.
92. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki‐67) in breast carcinoma tissue sections.
93. p53 expression in breast cancer.
94. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.
95. Proliferation of invasive breast carcinomas and colorectal adenocarcinomas: an immunohistochemical in situ investigation with the monoclonal antibody Ki‐67.
96. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
97. The cellular protein p53 in human tumours.
98. p21 RAS protein expression in benign and malignant human breast.
99. Determination of growth fraction in benign breast disease (BBD) with monoclonal antibody Ki‐67.
100. In situ demonstration of renal tubular regeneration using the monoclonal antibody Ki‐67.
101. Growth fractions in human prostatic carcinoma determined by Ki‐67 immunostaining.
102. Use of the monoclonal antibody Ki‐67 in the study of the proliferative activity of urologic tumors. Preliminary data.
103. Immunocytochemical assays in human endometrial carcinomas: a multiparametric computerized analysis and comparison with nonmalignant changes.
104. Primary liver neoplasms: evaluation of proliferative index using MoAb Ki‐67.
105. Immunohistochemical detection of proliferating cells in colorectal carcinomas and adenomas with the monoclonal antibody Ki‐67. Preliminary data.
106. England J. Ki‐67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations.
107. Immunohistologic demonstration of abnormal colonic crypt cell kinetics in ulcerative colitis.
108. New approach to assessing lung tumours in man.
109. Immunocytochemical studies in the diagnosis of pulmonary histiocytosis
110. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading.
111. The Ki‐67 antigen in primary human melanomas—its relationship to mitotic rate and tumor thickness and its stability.
112. Expression of a cell‐cycle‐associated nuclear antigen (Ki‐67) in cutaneous lymphoid infiltrates.
113. Lymphomatoid papulosis expresses immunophenotypes associated with T cell lymphoma but not in inflammation.
114. Epidermal proliferation and accumulation of polymorphonuclear leukocytes in the psoriatic lesion.
115. Adult cutaneous hemangiomas are composed of nonreplicating endothelial cells.
116. Immunohistochemical analysis of sarcoid granulomas. Evaluation of Ki67 + and interleukin‐1 + cells.
117. Biological characterization of human bone tumours. X. The proliferation behaviour of macrophages as compared to fibroblastic cells in malignant fibrous histiocytoma and giant cell tumor of bone.
118. Photosensitive dermatitis with actinic reticuloid syndrome: an immunohistological study of the cutaneous infiltrate.
119. Allergic contact dermatitis: novel immunohistologic features.
120. Expression of the proliferation markers Ki67 and transferrin receptor by human trophoblast populations.
121. Proliferative activity in endometrial stromal granulocytes throughout menstrual cycle and early pregnancy.
122. Tumor cell growth fraction in Hodgkin's Disease.
123. Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody. Ki67.
124. Immunohistochemical characterisation of inflammatory cells in biopsies from atherosclerotic abdominal aortic aneurysms.
125. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture.
126. Determination of the proliferative fraction of a transplantable, hormone‐dependent, human prostatic carcinoma (PC‐82) by monoclonal antibody Ki‐67: potential application for hormone therapy monitoring.
127. Antiproliferative effect of interferon‐gamma in human endometrial epithelial cells in vitro: potential local growth modulatory role in endometrium.
128. Immunodetection in fine‐needle aspirates and multiparametric (SAMBA) image analysis
129. Image analysis applied to proliferating cells in malignant lymphoma.
130. Quantitation of estrogen receptor content and Ki‐67 staining in breast carcinoma by the MicroTICAS image analysis system.
131. A flow cytometric method for measuring lymphocyte proliferation directly from tissue culture plates using Ki‐67 and propidium iodide.
132. A method for measuring lymphocyte proliferation in mixed lymphocyte cultures using a nuclear proliferation antigen. Ki‐67, and flow cytometry.
133. Nucleolar organiser regions.
134. An immunological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery.
135. Immunocytochemical analysis of cytocentrifuged preparations. A study based on lung tumours aspirated in vitro.
136. Use of bronchial brushings in the immunocytochemical assessment of human lung tumours.
137. Monoclonal antibody Ki‐67 as a proliferation marker.
138. Cytoplasmic’ expression of nuclear antigens.